AOD-9604 Research Peptide 5mg AOD-9604 is a synthetic fragment of human growth hormone (amino acids 176-191), originally developed at Monash University
Clonogenic survival assay HCT116 cells were seeded at a density of 200 cells per well in a 6-well microtitre plate
To allow for adequate time on medication, and to capture a time period during which weight loss commonly plateaus or weight regain occurs when not using medication [40,41], participants had to be on the AOM for 618 months
According to the Phase 3b, double-blind, placebo-controlled STRIDE study, Ozempic (1 mg) resulted in a superior and clinically meaningful improvement of 13% in maximum walking distance and a mean treatment difference of 39.9 meters on a steep incline compared to placebo at week 52 in adults with T2DM and PAD. If approved, Ozempic will be the only GLP-1 receptor agonist indicated for the treatment of PAD in patients with T2DM
Common subcutaneous injection: 1-2 mg daily (Mon-Fri), 30 days on/14-30 off
